Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Allakos Inc. - Common Stock (NQ:ALLK)

0.2498 -0.0014 (-0.56%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 21, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Allakos Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
Benzinga's Top Ratings Upgrades, Downgrades For December 22, 2021
Upgrades According to Loop Capital, the prior rating for Williams-Sonoma Inc (NYSE: 
Via Benzinga
Allakos' Shares Nosedive After Lirentelimab Studies Fail To Achieve Statistical Significance On Symptomatic Endpoints
Allakos Inc (NASDAQ: ALLK) reported data from ENIGMA 2 Phase 3 study of lirentelimab in eosinophilic gastritis (EG) or eosinophilic duodenitis (EoD) and KRYPTOS Phase 2/3... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers BiondVax Pharmaceuticals (NASDAQ:BVXV) shares moved upwards by 54.72% to $2.29 during Wednesday's pre-market session. The company's market cap stands at $... 
Via Benzinga
The Daily Biotech Pulse: Allakos Slips Negative Late-Stage Data, Pfizer & Merck Announce Fresh COVID Pill Deal With UK, Regulatory Setback For Takeda
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Allakos's Lirentelimab Flunks Late-Stage Studies In Patients With... 
Via Benzinga
3 Biotech Stocks With Huge Catalysts Incoming
These drugmakers have big events that should occur before the end of 2021. 
Via The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For August 26, 2021
Upgrades Scotiabank upgraded the previous rating for Enerplus Corp (NYSE: 
Via Benzinga
3 Biotech Stocks That Could Double Soon
Wall Street analysts following these drugmakers think they can produce big gains in a short time frame. 
Via The Motley Fool
Exposures Product Safety
Benzinga's Top Ratings Upgrades, Downgrades For May 18, 2021
Upgrades Janney Montgomery Scott upgraded the previous rating for Centerspace (NYSE:CSR) from Neutral to Buy. In the first quarter, Centerspace showed an EPS of $0.95,... 
Via Benzinga
The Daily Biotech Pulse: Q1 Beat From Johnson & Johnson, KalVista Study Placed On Hold, European Label Expansion For GW Pharma's Epidiolex
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 15) Alexion Pharmaceuticals,... 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.